558results about "Hormone peptides" patented technology

The invention provides a method for synthesizing Cagrilintide by a large-fragment SPPS-LPPS mixing method. The method comprises the following steps: cutting the Cagrilintide into four polypeptide fragments, wherein sequences 1-14 are fragments I, sequences 15-26 are fragments II, sequences 27-35 are fragments III, and sequences 36-39 are fragments IV; coupling protected amino acid monomers at corresponding sequence positions one by one through SPPS to synthesize a full-protection fragment I, a fragment II and a fragment III, and synthesizing a fragment IV through a solid phase or a liquid phase; and carrying out repeated condensation / Fmoc removal reaction on the fragments by virtue of an LPPS (Liquefied Peptide Polystyrene) method, so as to obtain the fully-protected Cagrilintide. The total yield of synthesized Cagrilintide is about 45%, the purity is larger than 99.0%, the single impurity content is smaller than 0.1%, the process is simple, the production efficiency is greatly improved, and the method is more suitable for industrial production and has wide application prospects.

According to the laodelphax striatellus ecdysis gene LsMH and the application thereof in biological prevention and control of laodelphax striatellus, the laodelphax striatellus ecdysis gene LsMH serves as one of key genes for ecdysis of laodelphax striatellus, the laodelphax striatellus ecdysis gene LsMH can be subjected to targeted interference, laodelphax striatellus can be remarkably inhibited from forming adults through eclosion, and laodelphax striatellus death is avoided, so that laodelphax striatellus population is the harm of the laodelphax striatellus to food crops is reduced. The control of laodelphax striatellus is carried out through a biological means, the method is safe and harmless to environment ecology and food, and a new strategy is provided for green control of laodelphax striatellus. The dsRNA or the interference reagent is prepared through transcription of the laodelphax striatellus ecdysis gene LsMH, the LsMH gene can be effectively interfered after the dsRNA or the interference reagent is injected into the laodelphax striatellus, the phenomena that wings are bent or incomplete, the abdomen is wizened and ecdysis is incomplete occur in the ecdysis process of laodelphax striatellus nymphs, laodelphax striatellus eclosion into adults is inhibited, laodelphax striatellus death is avoided, and biological control over laodelphax striatellus is achieved.

To provide an adiponectin enhancer and an oral composition for enhancing adiponectin, having the effect of enhancing adiponectin.SOLUTION: An adiponectin enhancer comprises plasmalogen as an active ingredient.SELECTED DRAWING: Figure 1

The invention relates to the technical field of biological medicine, in particular to eye drops containing recombinant protein as well as a preparation method and application of the eye drops. Comprising the following components: 0.01%-1% of recombinant human TFF3 protein, 0.1%-1% of an osmotic pressure regulator, 0.08%-2% of a pH regulator, 0.05%-0.15% of a thickening agent, 0.01%-0.1% of a surfactant, 0.01%-0.1% of a protective agent and the balance of water for injection, the traditional Chinese medicine composition can be used for treating the xerophthalmia, can promote wound healing and cell migration, has the effects of inhibiting inflammation and cell apoptosis, and can act on a plurality of target spots at the same time, so that the tear film stability is improved, ocular surface inflammation is inhibited, the vicious circle of the xerophthalmia is broken, and the xerophthalmia is treated more comprehensively and effectively; the problems that in the prior art, xerophthalmia medicine targets are single, and xerophthalmia cannot be comprehensively and effectively treated are solved.

The invention provides a human amylin polypeptide analogue containing non-natural amino acid and application of a derivative of the human amylin polypeptide analogue to treatment of obesity and diabetes related diseases. The human amylin polypeptide derivative obtained by introducing non-natural amino acid into the N terminal of human amylin and modifying by albumin binding residues can effectively prevent enzymatic degradation, prolong the half-life period, participate in delay of gastric emptying and inhibition of postprandial glucagon release, can influence the rising speed of postprandial blood sugar through various mechanisms, and can be used for preparing the anti-hyperglycemia human amylin polypeptide derivative. The compound can be used for preventing or treating obesity, excessive ingestion, diabetes mellitus and other related metabolic diseases.

The invention discloses an SmCLE mature peptide and application thereof in plant stress resistance, and belongs to the technical field of plant biology. According to the technical scheme, the SmCLE mature peptide is provided, and the amino acid sequence of the SmCLE mature peptide is SEQ ID NO: 1. The CLE peptide is applied to the aspect of plant stress resistance, the problem that an existing CLE peptide cannot be applied to stress resistance of plants, especially medicinal plants or non-mode crops is solved, the CLE peptide has high biocompatibility and targeting performance, and the biomass and yield of the crops in a stress environment can be remarkably improved.

The invention relates to the technical field of biological medicine, and discloses an intestinal insulinotropic analogue with multiple biological activities, a synthesis method, a pharmaceutical composition and application, the synthesized intestinal insulinotropic analogue has triple agonist activity of a GLP-1 receptor, a glucagon receptor and a CCK-1 receptor, not only has the treatment effect of GLP-1 on diabetes, but also has the treatment effect of GLP-1 on CCK-1, and also has the effect of GLP-1 on CCK-1 on CCK-1. The traditional Chinese medicine composition also has the regulating effect of glucagon on lipolysis and energy metabolism and the beneficial effect of CCK on appetite inhibition, so that a synergistic effect is generated on sugar, fat and energy metabolism; the application has great potential in preparation of drugs for treating metabolic syndromes, such as diabetes, obesity, non-alcoholic fatty liver diseases, dyslipidemia and other diseases.

To provide a pharmaceutical GIP / GLP1 co-agonist peptide composition for subcutaneous injection.SOLUTION: A pharmaceutical composition for treating diabetes comprises: tirzepatide, or a pharmaceutically acceptable salt thereof; an agent selected from the group consisting of NaCl and propylene glycol; and dibasic sodium phosphate.SELECTED DRAWING: None

The invention provides a human amylin polypeptide analogue containing non-natural amino acid and a derivative of the human amylin polypeptide analogue. According to the present invention, the human amylin polypeptide derivative obtained by introducing the non-natural amino acid to the N-terminal of the human amylin and modifying with the albumin binding residue can effectively prevent enzymatic degradation and prolong the half-life period, and has characteristics of improved solubility and / or physical stability and / or bioavailability and / or pharmacokinetic properties, the compound can be used for treating obesity and obesity-related diseases.

The present disclosure relates in some aspects to methods and compositions for detecting an amyloid-related disease in an individual.

The present disclosure describes a GnRH therapeutic agent for neutralizing GnRH levels in a subject, which can reduce testosterone levels to attenuate or eliminate prostate cancer cell growth and / or metastasis. The therapeutic agent is synthetically produced. The GnRH therapeutic agent includes a hapten carrier (hC) comprising a monomeric peptide (MP) synthesized separately from the GnRH peptide. After self-assembly of the hC, GnRH is covalently coupled to form a GnRH-hC conjugate that can serve as a therapeutic agent. The MP comprises heptad repeats following a specific pattern. The hC can comprise a GnRH peptide bound to the monomeric peptide prior to self-assembly to form a therapeutic agent. Optionally, the GnRH-hC conjugate further comprises one or more T cell epitopes at the N- and / or C-termini of one or more amphipathic alpha helices. The present disclosure also describes compositions, including immunogenic compositions, comprising the therapeutic agents described herein.

A method for quantifying active orexin A in a specimen, comprising: a step of contacting the specimen with a monoclonal antibody that recognizes the C-terminal side of orexin A to separate orexin A species; a step of digesting the separated orexin A species with a protease to obtain a peptide consisting of an amino acid sequence of SEQ ID NO: 1; and a step of performing mass spectrometry on the peptide.

The invention relates to PYY analogues having alanine at position 4, lysine at position 7, QRY as the C-terminal end and a half-life extending group. The analogues of the invention are soluble around pH 6 and 7. The invention also relates to pharmaceutical compositions comprising such PYY analogues, and to the medical use of the analogues.

The disclosure provides compositions and methods for the treatment and / or prevention of sickle cell disease.

The present invention relates to the use of petrelintide to reduce body fat or inhibit gain of body fat whilst preserving lean mass.

The present invention provides an antibody pair that binds human mature prolactin, comprising: a monoclonal antibody 1 or an antigen-binding fragment thereof that binds to an N-terminal region of human mature prolactin, and a monoclonal antibody 2 or an antigen-binding fragment thereof that binds to a C-terminal region of human mature prolactin. The present invention also provides use of the antibody pair of the present invention in manufacturing a kit for measuring prolactin in a biological sample. The present invention also provides a monoclonal antibody or an antigen-binding fragment thereof that binds to an N-terminal region of human mature prolactin and a monoclonal antibody or an antigen-binding fragment thereof that binds to a C-terminal region of human mature prolactin, respectively. The present invention also provides a method for measuring prolactin in a biological sample using the antibody pair of the present invention. The present invention also provides a method for producing a monoclonal antibody in the antibody pair of the present invention.

The invention relates to a polypeptide analogue or a derivative thereof as well as a preparation method and application thereof, in particular to an agonistic polypeptide analogue of an insulin amyloid polypeptide receptor or a derivative thereof. The polypeptide analogue or the derivative thereof provided by the invention has good agonism on an insulin amyloid polypeptide receptor, has the characteristics of good stability, high activity and the like, and can be used for treating and preventing diseases related to the insulin amyloid polypeptide receptor, such as abnormal weight, especially obesity and overweight.

The invention relates to the technical field of polypeptide drugs, in particular to a preparation method of amylin analogues. The preparation method of the amylin analogue comprises the following steps: (a) sequentially coupling Fmoc-protected amino acids and eicosanedioic acid mono-tert-butyl ester to resin from a C terminal to an N terminal according to a peptide sequence of the amylin analogue by adopting a solid-phase synthesis method to obtain straight-chain peptide resin; (b) removing side chain protecting groups of Asp at the position 3 and Lys at the position 8 of the straight-chain peptide resin, carrying out cyclization reaction to form a lactam bridge, and carrying out cracking treatment to obtain an amylin analogue; wherein the amino acid protected by the Fmoc is selected from any one of Fmoc-(Dmb) Gly-OH and Fmoc-(Hmb) Gly-OH when the fourth-site Gly in the coupling peptide sequence is coupled. According to the preparation method of the amylin analogue, under the condition that reaction steps are not increased, the occurrence probability of side reactions is remarkably reduced, the product purity is improved, and the purification difficulty is reduced.

The invention relates to PYY analogues having alanine at position 4, lysine at position 7, QRY as the C-terminal end and a half-life extending group. The analogues of the invention are soluble around pH 6 and 7. The invention also relates to pharmaceutical compositions comprising such PYY analogues, and to the medical use of the analogues.

To provide suitable formulations of CNP conjugates comprising CNP covalently linked via a reversible linker to a polymeric moiety, where the peptide will exhibit an acceptable impurity profile and limited premature CNP release even after extended storage.SOLUTION: A dry pharmaceutical formulation is provided. The pharmaceutical formulation comprises a CNP conjugate, a buffering agent, and a bulking agent. The CNP conjugate comprises a CNP moiety that is covalently and reversibly conjugated to a polymeric moiety.SELECTED DRAWING: None

The invention relates to the field of biological medicine preparation, in particular to a semi-synthesis preparation method of canagliflozin, which comprises the following steps: (1) under the condition that the pH value is 9.0-11.5, carrying out selective protection on lysine epsilon amino of a canagliflozin intermediate 36AA to obtain Boc-protected 36 peptide (BoC-36AA); (2) under the condition that the pH (Potential of Hydrogen) is 8.5 to 9.0, carrying out a reaction on side chain Glu-eicosandioic acid and the lysine alpha-amino group of the Boc-36AA to obtain 36-AA (SC-36AA) with a side chain; (3) carrying out a reaction on the SC-36AA and prolinamide, so as to obtain a canagliflozin precursor; and (4) cracking the canagliflozin precursor to obtain the canagliflozin. The preparation method is simple to operate, low in cost, high in yield and high in purity, the total reaction yield is more than 56%, and the HPLC (high performance liquid chromatography) purity is more than or equal to 99.6%.

Provided is a method for promoting sexual maturity in fish, comprising a step for inhibiting functional expression of at least one of a leptin receptor and leptin in fish. The present invention addresses the problem of providing a method for promoting sexual maturity of a fish in order to obtain an individual fish capable of ovulating or spermising at an age of 1 more than under natural or conventional culture conditions.

Hybrid peptide compounds having a modified lysine residue are described herein.

To develop a more efficient and cost-effective method to produce therapeutics for treating prostate cancer.SOLUTION: Provided is a GnRH therapeutic for neutralizing GnRH levels in a subject, which can reduce testosterone levels to attenuate or eliminate prostate cancer cell growth and / or metastasis. The therapeutic is produced synthetically. The GnRH therapeutic comprises a hapten carrier (hC) including a monomeric peptide (MP) synthesized separately from the GnRH peptide, and after self-assembly of the hC, GnRH is covalently coupled to form a GnRH-hC conjugate that can serve as a therapeutic. The MP includes heptad repeats following a specific pattern. The hC may include a GnRH peptide attached to a monomeric peptide prior to self-assembly to form a therapeutic. Optionally, the GnRH-hC conjugate further comprises one or more T cell epitopes at the N- and / or C-terminus of one or more amphipathic alpha-helices. Also provided are compositions including immunogenic compositions comprising the therapeutic.SELECTED DRAWING: None

Described herein are compositions for modulating transgene expression of one or more therapeutics. In some aspects, an engineered polynucleotide comprising one or more expression cassettes encoding a first angiogenesis inhibitor and a second angiogenesis inhibitor. Also described herein are methods for using the compositions described herein for modulating transgene expression and for treating a disease or condition, in particular therapeutics for treating ocular diseases or inhibiting neovascularization.

The technology described herein is directed to probiotic microbes engineered to secrete at least one enteroendocrine modulating polypeptide, which can be a sweet protein. In some embodiments, the probiotic microbe secretes the enteroendocrine modulating polypeptide in the distal colon. Also described herein are nucleic acids or vectors comprising a coding sequence for the enteroendocrine modulating polypeptide. Also described herein are compositions comprising the engineered probiotic microbe. Methods of using such probiotic microbes and compositions are also disclosed, including methods for modulating enteroendocrine cells and methods for treating metabolic diseases.

The invention discloses a preparation method of Retatrutide, and belongs to the technical field of polypeptide synthesis. The invention relates to a preparation method of Retatrutide, which comprises the following steps: by taking Sieber amide resin as a coupling resin carrier, sequentially coupling and inoculating Fmoc protected amino acid and dipeptide and tripeptide protected amino acid fragments, and then cutting the resin to prepare a peptide fragment I, namely an intermediate M1; cTC resin is used as a coupling resin carrier, Fmoc protected amino acid and oligopeptide protected amino acid fragments are sequentially coupled and connected, then the resin is cut, and a peptide fragment II, namely an intermediate M2, is prepared; coupling the intermediate M1 and the intermediate M2 to prepare full-protection Retatrutide, namely an intermediate M3, and cracking the intermediate M3 by using a cracking agent to remove a protective functional group, so as to obtain a crude Retatrutide product; and dissolving, filtering, purifying, and freeze-drying to obtain a Retatrutide refined product. Two long peptide fragments and a plurality of protected amino acid fragments are used for preparing Retatrutide, the generation of impurities is reduced, the single impurity is small, the purification difficulty is reduced, the product purity is ensured, and the purity of the obtained product is greater than 98.0%.

The present invention provides a method for improving glycemic control in a patient in need thereof, comprising administering to said patient, tirzepatide, or a pharmaceutically acceptable salt thereof, wherein said patient has failed to reach their HbA1c goal using GLP-1 RA treatment. The present invention provides a method for improving weight management in a patient in need thereof, comprising administering to said patient tirzepatide, or a pharmaceutically acceptable salt thereof, wherein said patient has failed to reach their weight management goal using GLP-1 RA treatment.

The preparation method comprises the following steps: according to an Fmoc solid-phase synthesis method, adopting Sieber resin as a solid-phase synthesis carrier, and sequentially coupling to obtain full-protection peptide resin; cutting the fully-protected peptide resin by using a DCM solution of TFA with a volume fraction of 3-5%, filtering to remove waste resin, and concentrating the obtained filtrate into a viscous solid; and adding a cracking reagent into the viscous solid, carrying out cracking, adding an ether solvent after the cracking is finished, carrying out sedimentation, and filtering and drying a precipitate to obtain a crude product of the tilpotide. By adopting the method disclosed by the invention, the use amount of TFA can be reduced by 70%, the use amount of ether as a required settling solvent is also reduced by 90%, precipitated particles are easily filtered by using filter cloth or filter paper, the limitation of the volume of a settling kettle on cracking batches is solved, the problem of solid-liquid separation of settling liquid is solved, the production efficiency is greatly improved, and the production cost is reduced.

Hybrid peptide compounds having a substituted tryptophan residue or a terminal substituent are described herein.